Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pharming Group NV (PHGUF : OTC)

• Company Description    Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. Number of Employees: 426

• Price / Volume Information    Yesterday's Closing Price: $1.50 Daily Weekly Monthly 20 Day Moving Average: 0 shares Shares Outstanding: 671.07 (millions) Market Capitalization: $1,006.61 (millions) Beta: 0.63 52 Week High: $1.50 52 Week Low: $0.75 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -0.61% 12 Week 30.43% 23.75% Year To Date 52.83% 33.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Darwinweg 24 - Leiden,P7 2333 CR NLD ph: 31-0-71-524-7400 fax: 31-0-71-524-7445 investor@pharming.com http://www.pharming.com

• General Corporate Information    Officers Sijmen de Vries - Chief Executive Officer Richard Peters - Chairperson Deborah Jorn - Vice Chairperson Mireille Sanders - Chief Operations Officer Jeroen Wakkerman - Chief Financial Officer Peer Information Pharming Group NV (CORR.) Pharming Group NV (RSPI) Pharming Group NV (CGXP) Pharming Group NV (BGEN) Pharming Group NV (GTBP) Pharming Group NV (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N69603145 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 671.07 Most Recent Split Date: 3.00 (0.10:1) Beta: 0.63 Market Capitalization: $1,006.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.20 Price/Cash Flow: 199.61 Price / Sales: 2.96 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 150.00% Sales Growth vs. Year Ago Period: 25.79% vs. Previous Quarter: 17.83% ROE 09/30/25 - - 06/30/25 - -3.31 03/31/25 - -6.01 ROA 09/30/25 - - 06/30/25 - -1.78 03/31/25 - -3.23 Current Ratio 09/30/25 - - 06/30/25 - 2.79 03/31/25 - 2.76 Quick Ratio 09/30/25 - - 06/30/25 - 2.07 03/31/25 - 2.00 Operating Margin 09/30/25 - - 06/30/25 - -2.19 03/31/25 - -4.14 Net Margin 09/30/25 - - 06/30/25 - -2.19 03/31/25 - -4.14 Pre-Tax Margin 09/30/25 - - 06/30/25 - 1.04 03/31/25 - -1.14 Book Value 09/30/25 - - 06/30/25 - 0.36 03/31/25 - 0.32 Inventory Turnover 09/30/25 - - 06/30/25 - 0.60 03/31/25 - 0.60 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.50 03/31/25 - 0.51 Debt-to-Capital 09/30/25 - - 06/30/25 - 33.15 03/31/25 - 33.89

Powered by Zacks Investment Research ©